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Abstract:  
Bifunctional inhibitors from the Kunitz-type soybean trypsin inhibitor (STI) family are glycosylated proteins able 
to inhibit serine and aspartic proteases. Here we report six crystal structures of the wild-type and a non-
glycosylated mutant of the bifunctional inhibitor E3Ad obtained at different pH values and space groups. The 
crystal structures show that E3Ad adopts the typical β-trefoil fold of the STI family exhibiting some conformational 
changes due to pH variations and crystal packing. Despite the high sequence identity with a recently reported 
potato cathepsin D inhibitor (PDI), three-dimensional structures obtained in this work show a significant 
conformational change in the protease-binding loop proposed for aspartic protease inhibition. The E3Ad binding 
loop for serine protease inhibition is also proposed, based on structural similarity with a novel non-canonical 
conformation described for the double-headed inhibitor API-A from the Kunitz-type STI family. In addition, 
structural and sequence analyses suggest that bifunctional inhibitors of serine and aspartic proteases from the 
Kunitz-type STI family are more similar to double-headed inhibitor API-A than other inhibitors with a canonical 
protease-binding loop.  
Keywords: aspartic protease inhibitors, Kunitz-type STI family inhibitors, bi-functional inhibitors, plant protease 
inhibitors, β-trefoil fold 
Abbreviations: BASI, barley alpha-amylase/subtilisin inhibitor; EcTI, Enterolobium contortisiliquum trypsin 
inhibitor; PSPI, potato serine protease inhibitor; API-A, Arrowhead proteinase inhibitor A; PDI, potato cathepsin 
D inhibitor; STI, soybean trypsin inhibitor; SLAPI, Solanum lycopersicum aspartic protease inhibitor; TKI, 
Tamarind Kunitz-type inhibitor.  
Introduction 
Protease inhibitors are an effective way to regulate the activity of target proteases, with great interest in those 
involved in biomedical and biotechnological processes. Among the different protease inhibitor families, 
proteinaceous serine protease inhibitors are probably the most studied and widespread in nature (Otlewski et 
al., 2001; Tyndall et al., 2005).  
Inhibitors of the Kunitz-type soybean trypsin inhibitor (STI) family are among the most versatile protease 
inhibitors reported, being able to interact with proteases belonging to different mechanistic classes like serine, 
aspartic and cysteine proteases, as well as other enzymes: α-amylase and sucrose invertase (Azarkan et al., 
2011; Cater et al., 2002; Fischer et al., 2015; Franco et al., 2002; Glaczinski et al., 2002; Keilová H. and Tomášek, 
1976a). These inhibitors have a β-trefoil fold, composed of 12 β-strands arranged in three-fold pseudo-symmetry 
units or subdomains with the presence of helices in some cases (Broom et al., 2012; McLachlan, 1979; Murzin 
et al., 1992; Renko et al., 2012). The pseudo-symmetry units are composed of four β-strands, two of them 
forming a six-stranded β-barrel with the other subdomains, and the other two of each unit forming a β-hairpin 
acting like the cap for the β–barrel. The structural regions reported to be involved in protease-inhibitor 
interactions are loops connecting the β-strand elements (i.e. loop L4 between β-strands 4 and 5 in STI), which 
can be highly variable in sequence and length (Renko et al., 2012). The most accepted model for the β-trefoil 
fold evolution proposes that the fold arose from a duplication and fusion of the monomeric unit from an ancestral 
trimeric protein (Broom et al., 2012; Ponting and Russell, 2000).  
There are several structural and functional studies defining the inhibition mechanism for serine proteases 
(Laskowski and Kato, 1980; Radisky and Koshland, 2002; Song and Suh, 1998; Zakharova et al., 2009). Among 
the proteinaceous protease inhibitors, almost all Kunitz-type STI inhibitors have a “canonical” conformation in 
the protease-binding loop that interacts with the active site of the serine proteases forming a substrate-like 
“Michaelis” complex and thereby implicated directly in their biological activity (Song and Suh, 1998; Zhou et al., 
2013). In the inhibition mechanism, the enzyme is able to hydrolyze the peptidic bond between P1-P1´ positions 
(Schechter & Berger Pn-Pn´nomenclature) (Schechter and Berger, 1967) but the product retains a similar 
conformation with respect to the intact inhibitor, trapping the enzyme in a hydrolysis/re-synthesis cycle 
(Zakharova et al., 2009). The amino acid sequence of these “canonical” protease-binding loops can be variable, 
although there are certain preferences for basic amino acids (Lys and Arg) in the P1 position for trypsin (E.C. 
3.4.21.4) and the amino acids Tyr, Trp, Phe, Leu and Met in the case of chymotrypsin (E.C. 3.4.21.1) (Tyndall 
et al., 2005). Despite the variability among amino acid sequences, the conformation of the protease-binding 
loops are kept unchanged (Laskowski and Qasim, 2000). Generally, positions P3-P3´ are key determinants of 
the reactive loop conformation, with the P1 position comprising up to 50% of the enzyme-inhibitor interface 
contact area (Krowarsch et al., 2003). However, there is at least one case reported where a double-headed 
inhibitor has a binding loop with a non-canonical conformation, forming an enzyme-inhibitor complex with trypsin 
(Bao et al., 2009).  
In the case of Kunitz-type STI inhibitors from legume seeds, a sub-classification has been proposed based on 
the numbers of cysteines in the sequence (Oliva et al., 2010). Specifically in potato, a different classification has 
been proposed to divide the proteinaceous inhibitors into five groups with the best characterized proteins 
belonging to groups A, B and C (Bauw et al., 2006; Heibges et al., 2003a). It has been shown that there is a 
great sequence variability in the Kunitz-type STI inhibitors in potato, which has been linked to an adaptive 
mechanism in response to pathogens or even the acquisition of new functions to enhance their adaptability 
(Heibges et al., 2003b). Recently, a cDNA library was obtained from several potato cultivars and some proteins 
were heterologously expressed and tested against different classes of proteases. This work showed that 
inhibition of aspartic proteases is also possible in potato protease inhibitors belonging to group B (Fischer et al., 
2015).  
Despite the wealth of data regarding the inhibition process for serine proteases, very little is known concerning 
the structural determinants for the inhibition of aspartic proteases by inhibitors from the Kunitz-type STI family. 
Although first studies on bi-functional inhibitors of the Kunitz-type STI family against aspartic proteases were 
performed using human cathepsin D (EC 3.4.23.5) (Keilová H. and Tomášek, 1976b), to date there is evidence 
that Kunitz-type STI family members are also able to inhibit other aspartic proteases of the clan AA, family A1, 
such as saccharopepsin (EC 3.4.21.41) (Cater et al., 2002), memapsin 1 (EC 3.4.23.45) (Fischer et al., 2015), 
and Plasmepsin II (EC 3.4.23.39) (this work).  
Until recently, structural studies of proteinaceous inhibitors of aspartic proteases were limited with only four three-
dimensional coordinates available in the PDB from four different families in the MEROPS database (Rawlings et 
al., 2014): inhibitor SQAPI, family I25 (Headey et al., 2010, PDB code: 2KXG); inhibitor PI3, family I33 (Ng et al., 
2000, PDB codes: 1F32 and 1F34), inhibitor IA3, family I34 (Li et al., 2000, PDB code 1DPJ) and potato 
cathepsin D inhibitor (PDI), family I3 (Guo et al., 2015, PDB code: 5DZU). Only for the inhibitors PI3 and IA3 are 
there three-dimensional coordinates of the inhibitors in complex with target aspartic proteases (Pepsin and 
saccharopepsin; PDB codes: 1F34 and 1DPJ, respectively). However, there are no similarities in the amino acid 
sequences, three-dimensional structures or inhibition binding modes between these distinct families, making 
extrapolations to other proteinaceous protease inhibitors impossible.  
Previous computational analyses based on comparative protein modeling and docking studies, predicted loop 
L9 in the Solanum lycopersicum (tomato) aspartic protease inhibitor (SLAPI), as a key region involved in the 
inhibitor interaction with saccharopepsin´s active site (Guerra et al., 2012). A recent paper that describes the 
crystallographic structure of PDI also suggests the same structural region –the loop from Cys142 to Ala160 in 
PDI- as a binding loop for cathepsin D (Guo et al., 2015). Based on docking studies, Guo and colleagues, 
propose a second possible binding loop (loop L5) for cathepsin D running from Phe85 to Ile98.  
In the present work we report six crystal structures, obtained at different pH values (3.0, 3.5, 7.0, 7.2, 7.4 and 
9.0) and space groups (C2221, P22121 and P4322), of a potato bi-functional inhibitor of the Kunitz-type STI family 
that is able to inhibit the serine protease bovine trypsin and the aspartic protease Plasmepsin II. Despite, the 
close sequence identity with the potato cathepsin D inhibitor recently reported by Guo and colleagues, our crystal 
structures show significant differences in loop conformations, especially in loop L9. The analysis of the structural 
similarities with other inhibitors of the same family, as well as docking-modeling studies suggests loop L5 and 
L9 as potential binding loops for serine and aspartic proteases, respectively.  
Methods 
DNA isolation and cloning 
Genomic DNA from Solanum tuberosum (potato) Estima variety was isolated using the plant CTAB method 
(ABgene). Primers designed based on the API-8 inhibitor sequence (Strukelj et al., 1992) were used to amplify 
the inhibitor sequences and clone them in the pGEMT vector (Promega) and positive clones were sequenced. 
Among the sequences obtained, clone E3Ad, which does not contain introns and matched with GenBank entries 
XP_006362668.1 and XM_006362606.2, was selected for protein expression and re-amplified to introduce 
restriction sites for XhoI and Sac II, for subcloning in the vector pPICZαC, in frame with the α-factor secretion 
signal (Table S1). The mutant E3Ad_N19D was generated to delete the only glycosylation site on the E3Ad 
inhibitor using the construct pPICZαC-E3Ad as template (Table S1) with the QuickChange Multi-Site-Directed 
Mutagenesis Kit (Agilent). The clones were sequenced to verify the N19D mutation. The plasmid construct was 
linearized with the restriction enzyme Sac I and transformed into the yeast Pichia pastoris (GS115 strain) using 
the Pichia EasyComp Kit (Life Sciences). Positive clones were checked by colony PCR with 5´AOX1 and 3´AOX1 
primers.  
Expression and purification of inhibitors 
A single colony expressing the inhibitor E3Ad or E3Ad-N19D was inoculated and pre-cultured in 120 mL of 
BMGY medium (2% tryptone, 1% yeast extract, 0.1 M potassium phosphate, pH 6.0, 1.34% yeast nitrogen base, 
40 µM biotin, 1% glycerol) in baffled flasks at 30°C and 200 rpm for 24h. Cells were harvested by centrifugation 
at 3000 x g for 10 min at RT and washed with BMMY (2% tryptone, 1% yeast extract, 0.1 M potassium phosphate, 
pH 6.0, 1.34% yeast nitrogen base, 40 µM biotin, 1% methanol) medium and harvested as previously described. 
Expression of the inhibitors was achieved by re-suspension in BMMY medium to a final OD600nm of 1.0. 
Recombinant Pichia pastoris cells were incubated with continuous shaking at 28 °C and 200 rpm for 72h. 
Methanol (100%) was added every 24 h to a final concentration of 1% to maintain induction. Cells were harvested 
by centrifugation at 3000 x g for 10 min at RT and discarded. The supernatant was used for protein purification.  
Culture supernatant was extensively dialyzed against 10 mM sodium formate pH 4.0 buffer at 4 °C. The dialysate 
was adjusted to 150 mM NaCl and applied to a HiPrepTM SP-Sepharose HP column (GE Healthcare Life 
Sciences). Inhibitors were eluted using a linear gradient of 150-490 mM of NaCl in 10 mM sodium formate pH 
4.0 buffer. Fractions were analyzed by SDS-PAGE, pooled and concentrated using 10 kDa cut-off centrifugal 
filter units (Millipore). Concentrated samples of the inhibitors were applied to a Superdex 75 10/30 HR column 
(GE Healthcare Life Sciences) equilibrated with 10 mM sodium formate, 150 mM NaCl pH 4.0, coupled to an 
Äktapure system (GE Healthcare Life Sciences). Fractions were analyzed by SDS-PAGE and those containing 
the inhibitor were pooled.    
Crystallization 
Purified inhibitors were concentrated up to 10 mg/mL using centrifugal filter units with a 10 kDa cut-off (Millipore). 
Crystallization conditions were screened by the microbatch method using Wizard Classics (I-IV) (Emerald 
Biosciences) kits at 4 ºC and 18 ºC.  The sitting-drop vapour-diffusion method was used for crystal optimization, 
with drops consisting of 1 µL of protein and 1 µL of reservoir solution against 0.5 mL of reservoir solution. 
Promising conditions were further optimized with the use of Hampton Research Additive Screen™. Final pH 
values were measured using a pH meter.   
Diffraction quality crystals for mutant E3Ad_N19D were obtained from 15% (w/v) PEG 20000, 0.1 M HEPES pH 
7.0, 30 mM glycyl-glycyl-glycine (Condition 1, final pH 3.0), 10% (v/v) MPD, 0.1 M Bicine pH 9.0 (Condition 2, 
final pH 9.0), 20% (w/v) PEG 8000, 0.1 M HEPES pH 7.5100 mM glycine (Condition 3, final pH 3.5) and 20% 
(w/v) PEG 8000, 0.1 M HEPES pH 7.5, 30 mM glycyl-glycyl-glycine (Condition 4, final pH 7.2). Crystals for E3Ad 
were grown in 10% (w/v) PEG 2000 MME, 0.1 M Tris-HCl pH 8.5, 0.2 M trimethylamine N-oxide30 mM glycyl-
glycyl-glycine (Condition 5, final pH 7.4) and 20% (w/v) PEG 3350, 0.1 M Tris-HCl pH 7.0, 0.2 M CaCl2 (Condition 
6, final pH 7.0). Single crystals were soaked in reservoir solution containing a cryoprotectant agent (30% (v/v) 
glycerol or 35% (v/v) PEG 200) and mounted in loops, before flash-cooling in liquid nitrogen at 100K. 
Data Collection and processing 
Data were collected at beamline 19ID of the Advanced Photon Source (APS) on an ADSC Q315r CCD detector 
and at beamline BL14-1 of the Stanford Synchrotron Radiation Lightsource (SSRL) on a MARmosaic 325 CCD 
detector. Indexing, integration and scaling was performed with XDS and XSCALE (Kabsch, 2010). The 
reflections of the crystals obtained in conditions 5 and 6 were anisotropic scaled using the web server Diffraction 
Anisotropy Server (http://services.mbi.ucla.edu/anisoscale/) (Strong et al., 2006). The Matthews coefficient was 
calculated using MATTPROB program (Kantardjieff and Rupp, 2003; Weichenberger and Rupp, 2014). 
Molecular replacement was performed with PHASER (McCoy et al., 2007) from the CCP4 suite (Winn et al., 
2011) using the crystallographic structure of the inhibitor PSPI (PDB code 3TC2, %ID 70.8) as the initial search 
model for data obtained in the APS. For diffraction data obtained in the SSRL, the structure obtained for inhibitor 
E3Ad_N19D at 2.45 Å (PDB code 5FNW) was used as template for molecular replacement. In all cases, a cycle 
of rigid-body refinement was performed with REFMAC5 (Murshudov et al., 2011). Model refinement was 
performed with alternate cycles of Phenix (Adams et al., 2010) and manual rebuilding with Coot (Emsley et al., 
2010). Model validation was performed with MolProbity (Chen et al., 2010).  
Enzymatic assays 
The aspartic protease Plasmepsin II was expressed and purified as described previously (Ramírez et al., 2009). 
A continuous enzymatic assay was performed using the chromogenic peptide Lys-Pro-Phe-Glu-Phe-Nph-Arg-
Leu (Nph: para-nitrophenylalanine) as substrate (84 µM final concentration, KM: 50.8 µM) and 100 mM NaAc pH 
4.4 as assay buffer. The reactions were followed at 310 nm in a Cary 60 spectrophotometer (Agilent, USA) at 
37°C. The enzyme concentration in the assay was 180nM, which was determined by active-site titration with 
Pepstatin A. 
Serine protease inhibition assay was performed with bovine trypsin (EC 3.4.21.4) from Sigma. A continuous 
enzymatic assay was performed using Nα-benzoyl-L-arginine p-nitroanilide (BAPNA) as substrate (1 mM final 
concentration, KM: 1 mM) and 20 mM Tris-HCl, 150 mM NaCl, 20 mM CaCl2 pH 8.0 as assay buffer. The reactions 
were followed at 405 nm in a Cary 60 spectrophotometer (Agilent, USA) at 25 °C. The enzyme concentration in 
the assay was 66 nM. 
For both assays, the enzyme and inhibitor were incubated for 5 min prior the addition of the substrate. The initial 
velocity was determined at different concentrations of inhibitor E3Ad_N19D using the Cary WinUV Kinetics v5.0 
software. Fractional residual activity (vi/v0) was calculated from initial reaction velocities for different inhibitor 
concentrations with respect to an assay in the absence of inhibitor. All assays were performed in triplicate. Kiapp 
values were obtained by non-linear regression fitting of the data to the Morrison equation (Equation 1) (Bieth, 
1995; Morrison, 1969) with the program Statistica v7.0 (Statsoft). Ki values were calculated using Equation 2, 
considering a competitive binding mode, as previously reported for other related bifunctional inhibitors (Keilová 
H. and Tomášek, 1976b).   �i�Ͳ = ͳ − ሺ[�]Ͳ+[�]Ͳ+�iappሻ−√ሺ[�]Ͳ+[�]Ͳ+�iappሻ2−4[�]Ͳ[�]Ͳ2[�]Ͳ        (1) 
To calculate the stoichiometry of the Trypsin-inhibitor interaction, the enzyme concentration in the assay was 
increased to be under titration conditions ([E]0/Kiapp=15). Under these conditions, the curve vi/v0 vs [I]0/[E]0 shows 
a biphasic behaviour with the x axis intercept being the point where all the enzyme is bound to the inhibitor 
present in the assay.  
 
                                                Kiapp=Kiሺͳ+ [�]Ͳ�M ሻ                                            (2)  
 
Sequence and structural comparison 
Multiple sequence and structural alignments were performed using T-Coffee 
(http://tcoffee.crg.cat/apps/tcoffee/index.html) (Di Tommaso et al., 2011) and PDBeFold 
(http://www.ebi.ac.uk/msd-srv/ssm/) (Krissinel and Henrick, 2004) web servers, respectively. The final multiple 
sequence alignment (MSA) was manually parsed using the results obtained from both alignments.  A 
phylogenetic consensus tree was calculated from the curated MSA obtained previously using the Maximum 
Likelihood method based on the JTT matrix-model and 1000 bootstrap replicates, using the program MEGA6 
(Jones et al., 1992; Tamura et al., 2013). Pairwise whole protein and specific loop structural superpositions were 
performed with the Secondary Structure Matching (SSM) and Least-squares (LSQ) superposition modules 
respectively in the program Coot (Emsley et al., 2010),. 
The root mean square fluctuation (RMSF) among the heavy atoms of all the X-ray structures determined for 
E3Ad and E3Ad_N19D inhibitors were calculated using the g_rmsf tool of the GROMACS software package 
(version 4.6.5) (Páll et al., 2015). For this analysis the structure of the inhibitor E3Ad_N19D at pH 3.0 (PDB code: 
5FNW) was used as the reference.  
 The metaPPISP web server (http://pipe.scs.fsu.edu/meta-ppisp.html) (Qin and Zhou, 2007) was used to predict 
potential protein-protein interaction sites based on the three-dimensional structures obtained for the inhibitors 
E3Ad_N19D and PDI.  All the residues with a final score above 0.34 were considered as a positive prediction, 
as suggested by the authors. Rigid body docking was performed with the ClusPro 2.0 web server 
(https://cluspro.bu.edu/login.php) (Comeau et al., 2004a) using a crystal structure of Plm II in its free form (PDB 
code: 1LF4) and the structure of the inhibitor E3Ad_N19D at pH 3.0 (PDB code: 5FNW).  
Molecular Dynamics  
Energy Minimizations (EM) and Molecular Dynamics (MD) simulations were carried out using the GROMACS 
software package (version 4.6.5) (Páll et al., 2015) with the AMBER99sb force field (Hornak et al., 2006), and 
the TIP3P water model (Price and Brooks, 2004). The simulation systems consist of each inhibitor (PDI or 
E3Ad_N19D) solvated in a dodecahedron box with 7414 water molecules. The protonation states of ionizable 
residues were assigned at pH 4.4 or pH 8.0 with the program PDB2PQR (http://nbcr-
222.ucsd.edu/pdb2pqr_1.8/), which uses PROPKA for the prediction of pKa values (Dolinsky et al., 2007). To 
achieve the electroneutrality in the system, Na+ and Cl- ions were added at an appropriate ratio to reach a NaCl 
concentration of 0.15 M. At each step, the electrostatic interactions were calculated with the particle-mesh Ewald 
method (Darden et al., 1993). Van der Waals interactions were described by a Lennard-Jones potential with a 
cutoff of 1.1 nm that was switched to zero between 1.0 and 1.1 nm. Dispersion corrections for energy and 
pressure were applied. The SETTLE algorithm (Miyamoto and Kollman, 1992) was used to constrain bonds and 
angles of water molecules and LINCS (Hess et al., 1997) was used for all other bonds, allowing a time step of 2 
fs. The equilibrium simulations were sampled for 100 ns, using the leapfrog dynamic integrator (Hockney, 1970) 
at 310 K and a constant pressure of 1 atm, using the weak coupling to the velocity rescaling thermostat (Bussi 
et al., 2007) and Parrinello-Rahman barostat (Nosé and Klein, 1983; Parrinello and Rahman, 1981), respectively. 
Snapshots were saved at 10 ps intervals. 
Results and Discussion 
Overall structure of the bi-functional inhibitors E3Ad and mutant E3Ad_N19D 
Inhibitors E3Ad and E3Ad_N19D crystallized in several conditions, with most of them belonging to tetragonal 
space group P4322, with one molecule in the asymmetric unit, and two crystals belonging to orthorhombic space 
groups C2221 and P22121 with two and one molecules in the asymmetric unit, respectively. Even though space 
group P22121 is non-standard, systematic absences and the final refinement of the model supported the space 
group assignation. Structures were obtained at different pH values and resolutions from 2.43 Å to 2.65 Å (Table 
1). Coordinates for more than 98% of the residues were clearly defined by the 2Fo-Fc electron density map, with 
the exception of residues Glu1 and Ser2 in all structures.   
High solvent content in most of the crystals may be responsible for the high B-values calculated for most of the 
structures (Table1). For the structures reported in this work, a sequential addition of the cryoprotectant to the 
crystallization drop was crucial in order to get well defined spots with a mosaicity below 1 degree. When the 
crystals were directly soaked in the cryoprotectant solution both resolution and mosaicity were always negatively 
affected, which seems to be a result of the high solvent content in most of our crystals.  
Table 1. X-ray statistics for the E3Ad and E3Ad_N19D structures. Values in parenthesis are for the highest 
resolution shell. 
Protein E3Ad_N19D E3Ad_N19D E3Ad_N19D E3Ad_N19D E3Ad E3Ad 
Condition (pH) 1 (pH 3.0)  2 (pH 9.0)  3 (pH 3.5) 4 (pH 7.2) 5 (pH 7.4) 6 (pH 7.0)  
Beamline 19ID (APS) 19ID (APS) BL14-1 (SSRL) BL14-1 (SSRL) BL14-1 
(SSRL) 
BL14-1 (SSRL) 
Wavelength (Å) 0.9792 0.9792 1.1807 1.1807 1.1807 1.1807 
Space group P4322 P4322 C2221 P4322 P4322 P22121 
Unit-cell parameters       
a (Å) 77.22 77.94 102.95 77.14 77.18 47.58 
b (Å) 77.22 77.94 114.24 77.14 77.18 56.45 
c (Å) 94.24 95.01 98.77 94.14 95.90 72.55 
α, ȕ, Ȗ (°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 
90.0 
90.0, 90.0, 90.0 
Mosaic spread (°)a 0.14 0.25 0.21 0.13 0.38 0.55 
Resolution (Å) 19.50-2.45 (2.50-
2.45) 
19.45-2.65 (2.75-
2.65) 
38.42-2.47 (2.57-
2.47) 
32.0-2.43 (2.53-
2.43) 
29.5-2.5 (2.57-
2.5) 
22.6-2.55 (2.62-
2.55) 
Rmerge (%)b 5.3 (63.5) 4.9 (57.1) 4.7 (63.9) 4.6 (62.8) 5.5 (72.8) 6.5 (24.1) 
Rmeas (%)c 5.4 (65.2) 5.1 (58.6) 5.0 (67.9) 4.7 (64.8) 5.7 (75.1) 7.0 (25.8) 
CC1/2 (%)d 99.9 (96.2) 100 (95.4) 100 (95.1) 100 (94.3) 100 (94.2) 99.9 (99.2) 
Completeness (%) 99.8 (100) 99.8 (100) 99.8 (100) 99.9 (100) 98.0 (74.1) 98.0 (75.8) 
I/σ(I) 38.01 (5.58) 40.61 (5.98) 28.06 (3.24) 42.13 (5.21) 33.82 (4.89) 21.69 (8.08) 
Multiplicity 18.5 (19.28) 18.3 (19.24) 8.59 (8.7) 16.4 (16.95) 16.2 (16.63) 7.73 (8.12) 
No. of observed reflections 20 3134 (12 053) 163 456 (17 575) 182 351 (20 413) 184 496 (21 020)  167 335 
(9378) 
51 340 (2876) 
No. of unique reflections 10 963 (625) 8 941 (913) 21 238 (2345) 11 223 (1240) 10 356 (564) 6 643 (354) 
Wilson plot B factor (Å2) 58.2 72.4 60.57 56.77 60.16 33.56 
Solvent content (%)  64.1 65.0 65.24 63.99 59.62 40.67 
R-factor (%) 20.9 20.8 22.53  19.85 22.80 18.1 
Free R-factor (%) 26.2 26.0 27.42 23.75 24.37 24.6 
RMSD bond lengths (Å) 0.010 0.012 0.010 0.009 0.010 0.009 
RMSD bond angles (°) 1.21 1.50 1.39 1.22 1.35 1.16 
No. of reflections in 
working set  
10 458 8545 20 203 10 664 9857 6332 
No. of reflections in test set 503 391 1035 559 499 311 
Mean protein B-factor (Å2) 58.0 70.0 65.10 58.10 67.40 34.10 
Ramachandran plote       
Most favored (%) 94.02 90.76 92.35 95.63 92.90 96.20 
Additional allowed (%) 4.89 7.61 7.38 3.83 6.56 3.80 
Outliers (%) 1.09 1.63 0.27 0.55 0.55 0.0 
PDB code  5FNW 5FNX 5FZY 5FZU 5G00 5FZZ 
aCalculated with XDS 
bRmerge = Σhkl Σi |Ii(hkl) - (I(hkl)| Σhkl Σi Ii (hkl), where Ii(hkl)and (I(hkl)) represent the diffraction-intensity values of the individual measurements and the 
corresponding mean values. The summation is over all unique measurements. 
cRmeas is a redundancy-independent version of Rmerge: Rmeas = Σhkl   {N(hkl)/[N(hkl)-1]}1/2 ΣI |Ii(hkl) – {I(hkl)}|/ Σhkl Σi Ii (hkl) 
dCC1/2 values are the half-set correlation coefficients (Karplus and Diederichs, 2012). 
eCategories defined by Molprobity 
 
All structures determined show the β-trefoil fold typical of Kunitz-type STI family inhibitors, with 12 antiparallel β-
strands arranged in three pseudo-symmetry elements composed of four β-strands each (Figure 1). The β-trefoil 
fold is composed of six β-strands forming a β-barrel (strands β1, β4, β5, β8, β9 and β12) and the other six β-
strands arranged as a lid for the barrel. Two β-strands from the barrel and two from the lid form each pseudo-
symmetry unit or subdomain. Three short 310 helices have been assigned in the E3Ad_N19D structures at pH 
3.0 (PDB code: 5FNW) and pH 3.5 (PDB code: 5FZY), as well as E3Ad structures at pH 7.0 (PDB code: 5FZZ) 
and pH 7.4 (PDB code: 5G00) comprising residues Arg29-Gly33 (310-A), Lys91-Tyr96 (310-B) and Cys152-
Gln156 (310-C). However, in the E3Ad_N19D structures at pH 7.2 (PDB code: 5FZU) and pH 9.0 (PDB code: 
5FNX) just two 310 helices have been assigned, running from residues Arg29-Gly33 and Val90-Val94 (PDB code: 
5FZU) or Val90-Val94 and Cys152-Gln156 (PDB code: 5FNX). The 2Fo-Fc electron density maps of the E3Ad 
and E3Ad_N19D inhibitor structures clearly showed the presence of three disulfide bridges between positions 
Cys48-Cys93, Cys142-Cys158 and Cys148-Cys152. These disulfide bridges are present in all Kunitz-type STI 
family inhibitors able to inhibit aspartic proteases characterized to date, except those classified as part of the 
group B (Cater et al., 2002; Fischer et al., 2015; Keilová H. and Tomášek, 1976a; Mares et al., 1989).  
 Figure 1. Overall three-dimensional structure of inhibitor E3Ad_N19D at pH 3.0. β-sheets are colored according 
the pseudo three-fold symmetry elements (A). Topology of the inhibitor E3Ad_N19D (B) Final (2Fo-Fc) electron 
density map around residues Cys149-Pro153 (Loop L9) contoured at 1.0σ (C). The figure was created with 
PyMOL Molecular Graphics System, Schrödinger, LLC (http://www.pymol.org).  
In the coordinates of the inhibitor 3EAd (PDB code: 5G00), an N-Acetyl-glucosamine (NAG) molecule was 
modeled linked to the Asn19. Mass spectrometry analysis of the purified inhibitor E3Ad showed that several 
glycoforms are present with two molecules of NAG linked to the Asn19 and a variable number of mannose units 
(results not shown). However, electron density was just visible for one molecule of NAG.  
The three-dimensional structures of the inhibitor E3Ad and the mutant E3Ad_N19D at different pH values and 
space groups are very similar, with RMSD values from 0.21 Å to 0.68 Å over 185 Cα atoms (Figure 2A). However, 
a more detailed analysis of RMSD differences among all the structures suggests that crystal packing is more 
important than pH for such differences (Supplementary Table S2). The main differences in the structures are 
located in loops L1 (28-32), L2 (42-46), and L5 (89-92) (Figure 2A and B). The presence of three 310 helices 
present in four crystal structures reported in this work (PDB codes: 5FNW, 5FZY, 5FZZ, 5G00) are located in a 
pseudo-symmetry equivalent position connected to one β-strand from the β-barrel and one β-strand from the lid 
(Figures 1 and 3). To our knowledge, this is the first report of a protein of the Kunitz-type STI family with three 
helices, with most of the other family members having one α-helix, like STI (PDB code: 1AVW), API-A (PDB 
code: 3E8L), DrTI (PDB code: 1R8N) or one (PDI (PDB code: 5DZU)) or two (PSPI (PDB code: 3TC2)) 310 
helices. In this last structure, the two 310 helices are in equivalent positions to our structures.  
  
 Figure 2. Structural superposition of all structures of inhibitor E3Ad and mutant E3A_N19D. 5FNW (red), 5FNX 
(green), 5FZY chain A (blue), 5FZY chain B (yellow), 5FZU (magenta), 5FZZ (cyan) and 5G00 (orange) (A). The 
root mean square fluctuation (RMSF) among the heavy atoms of all the X-ray structures determined using 
E3Ad_N19D structure with PDB code 5FNW as the reference (B).     
Sequence and structural analysis  
The amino acid sequence of inhibitor E3Ad matches with a computationally predicted protein from Solanum 
tuberosum (potato) (UniProt identifier: M1AKE5_SOLTU). The closest functionally characterized Kunitz-type STI 
inhibitor deposited in the UniProt database is API9_SOLTU (95.7% sequence identity) (Ritonja et al., 1990), 
which inhibit porcine pancreatic trypsin (E.C. 3.4.21.4), bovine chymotrypsin (E.C. 3.4.21.1), human leukocyte 
elastase (EC 3.4.21.37), human and bovine cathepsin D (EC 3.4.23.5) and Saccharopepsin (EC 3.4.21.41) 
(Cater et al., 2002; Pouvreau et al., 2001). The sequence identity of E3Ad with other inhibitors of the Kunitz-type 
STI family characterized so far are: PDI (90.4%) (Keilová H. and Tomášek, 1976a), SLAPI (76.1%) (Cater et al., 
2002), PSPI (71.2%) (Meulenbroek et al., 2012), Murraya koenigii miraculin-like protein (27.7%) (Gahloth et al., 
2010), TKI (26.1%) (Patil et al., 2012) EcTI (25.5%) (Zhou et al., 2013), API-A (24.5%) (Bao et al., 2009), BASI 
(23.6%) (Vallée et al., 1998) and STI (22.6%) (Song and Suh, 1998). Details of amino acid substitutions in key 
regions for Kunitz-type STI inhibitors are shown in figure 3.  
 Figure 3. Multiple sequence alignment of inhibitor E3Ad_N19D with other members of the Kunitz-type STI family 
for which three-dimensional structures are available, with the protease-binding loops identified. β-sheets are 
coloured according to the three-fold pseudo-symmetry sub-domain to which they belong. Blue and bold: 
protease-binding loops for serine proteases, red box: P1-P1´ residues, green numbers at the bottom show the 
disulfide bridge topology. The following UniProt identifiers were used for inhibitors: PDI (API11_SOLTU), PSPI 
(Q8S380_SOLTU), API-A (Q7M1P4_SAGSA), EcTI (ITRY_ENTCO), STI (ITRA_SOYBN), DrTI (DRTI_DELRE), 
α-amylase /subtilisin inhibitor from rice (IAAS_ORYSJ), ETI (IDE3_ERYCA), BASI (IAAS_HORVU), double-
headed winged bean alpha-chymotrypsin inhibitor (ICW3_PSOTE) and Tamarind Kunitz inhibitor 
(F4ZZG4_TAMIN). The figure was made with the ESPript 3.0 webserver (http://espript.ibcp.fr/ESPript/cgi-
bin/ESPript.cgi). 
The three-dimensional structure of, a potato cathepsin D inhibitor PDI that is closely-related to E3Ad (90.4% 
sequence identity) was reported very recently (Guo et al., 2015). The structural superposition of E3Ad_N19D 
structure (PDB code: 5FZU) with PDI, showed that they are very similar in the protein core but differ in the 
conformation of some loops, like L5 (Ans86-Ile98) L7 (Gly116-Tyr126) L8 (Ser132-Gly136) and L9 (Cys142-
Cys158). The E3Ad_N19D structure used for the superposition was selected considering similarity with the pH 
of the crystallization condition for PDI. One of most interesting features of this structural comparison is the 
significant conformational difference of the loop L9 (S141-A159) in the two structures (Figure 4). Most of the 
sequence differences between the inhibitors are located in this loop (10 out 17 residues) and also 
crystallographic packing is different in both cases, which could explain this difference in conformations. 
Interestingly, this loop was predicted in a previous study, using a combination of computational tools, as the 
region involved in aspartic protease inhibition (Guerra et al., 2012). In addition, in that work it was also predicted 
that residues I144, V148, L49, P151, F152 and R154 (tomato inhibitor numbering) could be involved in the 
difference in potency against the proteases cathepsin D and saccharopepsin reported previously for tomato and 
potato inhibitors (Cater et al., 2002), and all these residues are localized in loop L9.  
 
Figure 4. Structural superposition of E3Ad_N19D (5FZU, green) and PDI (5DZU chain A, magenta). Loop L9 is 
represented with a higher ribbon radius and the angle between equivalent residues Arg151 (5FZU) and Phe152 
(5DZU) is shown.   
A molecular dynamics simulation study was performed to explore whether these conformations could be a result 
of the crystal packing or could be possible in solution.  This analysis did not reveal large conformational changes 
at loop L9 of the E3Ad_N19D inhibitor but the results showed that loop L9 in PDI structure (5DZU) changes its 
conformation after 20 ns at pH 4.4 and 310 K (Figure S3). This conformational rearrangement was not observed 
in simulations of PDI at pH 8. This is quite interesting because it suggests that loop L9 in PDI could adopt a 
conformation more similar to the equivalent loop in the E3Ad inhibitor reported in this work.  
The analysis performed with the PISA server based on the crystal arrangement, suggested that the E3Ad_N19D 
inhibitor could exist as a dimer in solution, however, size exclusion chromatography profiles show that, at least 
at pH 4.0, E3Ad_N19D behaves as a monomer (Figure S2). A similar prediction was made for inhibitor PSPI 
(PDB code: 3TC2), which has been proved to be a monomer in solution (Meulenbroek et al., 2012).  
Enzyme Inhibition 
Inhibitor E3Ad_N19D showed a typical tight-binding behavior against the aspartic protease Plm II as well as the 
serine protease bovine trypsin with Ki values of 10.5 and 43 nM  respectively (Figure 5). These results prove that 
glycosylation is not essential for aspartic protease activity. Previous work has demonstrated that glycosylation 
was not essential for the inhibition of the serine protease trypsin by Kunitz-type STI family inhibitors (Bao et al., 
2009; Speranskaya et al., 2006). The structural superposition of coordinates of the inhibitor E3Ad and 
E3Ad_N19D showed that the presence of the sugar moiety does not make any significant change to the overall 
three-dimensional structure of the protein, which correlates well with the inhibitory activity assay results.  
A B  
Figure 5. Inhibition curves fitted to Morrison´s equation for inhibitor E3Ad_N19D against the proteases Plm II 
(A) and bovine trypsin (B).  
Based on structural analysis and the possibility that E3Ad_N19D could be able to interact with two molecules of 
trypsin in a similar way to that described for the inhibitor PSPI (PDB code: 3TC2), the stoichiometry of the trypsin-
E3Ad_N19D binding was calculated using an enzyme titration assay, and an [I]0/[E]0 value of 1.18 was obtained 
(Figure S1). This result proved that the inhibitor E3Ad_N19D interacts with just one molecule of trypsin. 
Protease-binding loop for serine proteases  
The Kunitz-type STI inhibitor protease-binding loops involved in serine protease inhibition are highly variable in 
sequence and length (Figure 3) with almost all cases adopting a canonical conformation at positions P3-P3´. For 
most of the Kunitz-type STI family inhibitors structurally characterized so far, the protease-binding loop for serine 
proteases is located between strands β4 and β5 (Loop L4), however there are some inhibitors where it lies 
between strands β2- β3 (Loop L2), β5-β6 (Loop L5) or β9-β10 (Loop L9) (Figure 3) (Azarkan et al., 2011; Bao 
et al., 2009). In addition, there is just one double-headed inhibitor (API-A) where one of its protease-binding 
loops (loop L5) adopts a novel, non-canonical conformation, and even has an unusual Leu P1 site, that was 
confirmed by site-directed mutagenesis experiments (Bao et al., 2009).   
The loop L4 in the E3Ad_N19D inhibitor is shorter and does not contain any equivalent amino acids for positions 
P1-P1´ in comparison with other members with a canonical conformation in this region (Figure 3). Besides, in all 
three-dimensional structures of the E3Ad/E3Ad_N19D inhibitors determined in this work, the conformation of the 
loop L4 is such that the end of the loop is oriented toward the N-terminus (or N-terminal part) of the protein and 
not protruding to the solvent, an orientation that might make it difficult to allow any interaction with the active site 
of a protease. Structural comparison of the E3Ad_N19D loop L5 with identified protease-binding loops for serine 
proteases present in other Kunitz-type STI family inhibitors, showed that the closest structural similarity is with 
the non-canonical loop L5 of API-A. The RMSD values ranged from 0.71 Å to 0.94 Å for residues Val85-Asp90 
(P3-P3') for the API-A inhibitor and residues Thr89-Val94 of the E3Ad and E3Ad_N19D inhibitors (Figure 6A, C). 
These RMSD values become even lower if we only consider positions P3-P2´ (0.13Å to 0.42 Å).  In contrast, 
when the structural superposition was made with the canonical binding loops (mainly L4), the RMSD values were 
much higher: 2.75 Å (PDB code: 4J2K), 2.79 Å (PDB code: 4AN6) and 2.72 Å (PDB code: 1AVW). Interestingly, 
the loop L5 of the inhibitors PDI and PSPI (both also isolated from potato), not only have a similar conformation 
(Figure 6A), but also have a 310 helix in equivalent residues to API-A and E3Ad_N19D.  Phylogenetic analysis 
showed that inhibitors E3Ad, PDI and PSPI are closer to API-A than to the canonical Kunitz-type STI family 
inhibitors such as, for example STI (Figure 6B). These results are similar to those obtained by Azarkan et al., 
2011, where they showed that API-A is evolutionarily closer to API8_SOLTU (an aspartic protease inhibitor from 
the Kunitz-type STI family) than to the canonical inhibitors of the Kunitz-type STI family. It is worth noting that 
proposed P1 residues for inhibitors PSPI and PDI are also located in loop L5, and, in both cases, they have a 
Lys in this position as in the E3Ad inhibitor (Figure 6C) (Guo et al., 2015; Meulenbroek et al., 2012). Lys is a 
preferred amino acid for the P1 position in protease-binding loop for serine proteases (Krowarsch et al., 2003; 
Tyndall et al., 2005). On the other hand, despite the fact that amino acid Leu92 present in E3Ad and PDI is not 
a common P1´ residue, the similar amino acid Ile is present in that position in inhibitors with canonical 
conformations like STI (PDB code: 1AVW), EcTI (PDB code: 4J2K), TKI (PDB code: 4AN4) (Patil et al., 2012) 
and in both protease-binding loops of the double-headed inhibitor API-A (PDB code: 3TC2) (Figure 4). 
 
Figure 6. Structural superposition of loop L5 of inhibitor E3Ad_N19D (5FZU, yellow) with non-canonical protease-
binding loop of API-A (3E8L, magenta), loop L5 from PDI (5DZU, salmon) and PSPI (3TC2, blue) (A). Consensus 
tree (1000 replicates) using the maximum likelihood method calculated for the multiple sequence alignment of 
Figure 3. (B). Sequences of the proposed P3-P3´ positions in loop L5 for inhibitors E3Ad_N19D, PDI, PSPI and 
API-A (C). 
Considering the phylogenetic relationship between E3Ad and API-A, a structural superposition of loop L9 of both 
inhibitors was performed taking into account that API-A´s loop L9 is a canonical protease-binding loop for serine 
proteases that has been validated by site-directed mutagenesis (Bao et al., 2009). However, there are several 
insertions in the loop L9 of E3Ad_N19D with respect to API-A and the RMSD values between both loops, 
considering Phe143-Cys148 (P3-P3´) of API-A and Ile148-Pro153 of E3Ad, is higher than 2.0 Å. This difference 
indicates that loop L9 in E3Ad inhibitor does not adopt a canonical conformation.  
In the case of inhibitor PSPI, Meulenbroek et al., 2012 proposed Phe75 as a P1 residue in a secondary protease-
binding loop, however, there is no equivalent amino acid in inhibitor E3Ad_N19D (Figure 3), which could explain 
why PSPI is able to interact with two serine proteases simultaneously while E3Ad_N19D interacts with just one 
(Figure S1). Considering all this evidence, we propose that inhibitor E3Ad (and E3Ad_N19D) could interact with 
trypsin through a non-canonical protease-binding loop (loop L5), with Lys91 and Leu92 as the P1-P1´residues.   
Protease-binding loop for aspartic proteases  
The case of proteinaceous inhibitors of aspartic proteases is quite different from serine proteases. To date, there 
are only two three-dimensional structures of protease-inhibitor complexes, with no amino acid sequence or 
structural similarity between the two inhibitors, or with other inhibitor families (Li et al., 2000; Ng et al., 2000). 
Previously, combining different computational tools, loop L9 of a tomato aspartic protease inhibitor of the Kunitz-
type STI family was predicted as the region responsible for the inhibition of aspartic proteases (Guerra et al., 
2012). More recently, Guo et al., 2015 also suggested that equivalent loop L9 in PDI inhibitor could be implicated 
in the inhibition of cathepsin D, although their favoured docking models place residue Lys91 (loop L5) interacting 
with catalytic aspartic acids of cathepsin D.   
The analysis of three-dimensional structures of inhibitor E3Ad_N19D and PDI with the metaPPISP web server 
predicted that in both cases loop L9 could be part of a Protein-Protein interface (Figure S4). In addition, inhibitor 
E3Ad_N19D (PDB code: 5FNW) was docked to a three-dimensional apo structure of Plm II (PDB code: 1LF4) 
using the ClusPro 2.0 web server (Comeau et al., 2004b). The solutions of the balanced and electrostatic 
coefficients were analyzed, and the top solutions for both coefficients placed the residue Arg151 (loop L9) at 
interaction distance from both catalytic aspartic acids (Asp34 and Asp214) (Figure 7A). The roles of basic 
residues in the inhibition of aspartic proteases have been described for self-inhibition of the aspartic proteases 
progastricin (Moore et al., 1995), pepsinogen (James and Sielecki, 1986), cathepsin D (Lee et al., 1998) and 
also for the complex saccharopepsin-inhibitor IA3 (Li et al., 2000). Loop L9 has been previously proposed as the 
region involved in aspartic protease inhibition (Guerra et al., 2012). Also, it is important to note that Cater et al., 
2002 reported that bond hydrolysis between residues Arg154-Gly155 (loop L9) of the tomato aspartic protease 
inhibitor SLAPI affects aspartic protease inhibition, doubling the Ki value against saccharopepsin. It is also 
interesting that loop L9 is in an equivalent sequence position to a canonical protease-binding loop used by the 
double-headed inhibitor API-A to interact with trypsin (Figure 3). Considering the present structural and 
computational analyses, results from Guo et al., 2015 may be explained by a conformational change of loop L9.  
Despite the fact that the docking results obtained by Guo et al., 2015 with the inhibitor PDI suggested a different 
protease-binding loop (loop L5) as their favoured interaction site for aspartic proteases, the results discussed in 
the present work reinforce our previous hypothesis about the protease-binding loop for aspartic protease 
inhibition (Guerra et al., 2012). A plausible explanation is that the specific conformation observed in the PDI 
structure for the loop L9 led to docking solutions where Lys91 is interacting with the active site of cathepsin D. 
To explore this option we performed a docking study with the coordinates of a molecular dynamics simulation 
(93.77 ns) with the structure 5DZU at pH 4.4 that showed a change in the conformation of the loop L9 and the 
same Plm II apo structure used in docking with E3Ad_N19D. The results showed that in top solutions PDI´s loop 
L9 is placed in the active site of Plm II, although there is no direct interaction with catalytic aspartic acids as 
shown for E3AD_N19D (Figure 7B). Even though this approach is theoretical, it is remarkable that the simulation 
suggested that if PDI´s loop L9 could adopt an extended conformation it could be possible for it to interact with 
the active site of an aspartic protease, just as has been modeled for the E3Ad_N19D inhibitor.   
 
Figure 7. Docking models of the complex between inhibitors E3Ad_N19D and PDI with Plm II. Interactions of the 
Arg151 of the inhibitor E3Ad_N19D (PDB code: 5FNW) with Plm II´s catalytic aspartic acids (A). Modeled 
interaction of coordinates of PDI (PDB code: 5DZU), after 93.77 ns of molecular dynamic simulation, with Plm II 
(B). Plm II and inhibitors (E3Ad_N19D and PDI) are shown in blue and salmon, respectively.  
The presence of a pseudo three-fold symmetry, as a result of double gene duplication and fusion events, has 
been suggested as a selective advantage to develop new functions (Eisenbeis and Höcker, 2010). Bi-functional 
inhibitors of the I85 family which shares the β-trefoil fold, although having low sequence similarity with Kunitz-
type STI family inhibitors, use loops located in different pseudo-symmetry elements to interact with serine and 
cysteine proteases (Renko et al., 2010). Maybe this fact could be related to a hypothesis proposing that ancestral 
reactive sites could evolve independently allowing the acquisition of a new functionality or sub-specialization 
(Christeller, 2005). Considering the present structural and computational analysis of this work, this hypothesis 
could explain what happened with loop L9 in bifunctional inhibitors of aspartic and serine proteases of the Kunitz-
type STI family. Of course this will need experimental studies to confirm or refute the relationship between 
aspartic and canonical serine protease-binding loops.  
Conclusions 
The crystallographic structures reported here show that inhibitor E3Ad maintains basically the same 
conformation at different pH values and crystal packings, with only minor changes in some of its loops L1, L2 
and L5. Moreover, the structural comparison with the closely-related inhibitor PDI suggests that loop L9 can 
adopt different conformations depending on pH, loop sequence and also crystal packing. Based on sequence 
and structural analysis we propose that protease-binding loops for serine and aspartic protease inhibition in 
E3Ad could be the loops L5 and L9, respectively. The proposed binding loops for serine and aspartic proteases 
for the bifunctional inhibitor E3Ad are in equivalent loops with two binding loops for serine proteases in the 
double-headed inhibitor API-A. In addition, phylogenetic analysis suggests that inhibitor E3Ad (and also PDI and 
PSPI) could have a closer evolutionary relationship with double-headed inhibitor API-A than with members of 
the Kunitz-type STI-family with canonical protease-binding loops. Whether the inhibition of aspartic proteases in 
the particular case of the Kunitz-type STI inhibitor family could have evolved from a loop used for serine protease 
inhibition or not, is an intriguing question that a three-dimensional structure of a complex between an aspartic 
protease and a bifunctional inhibitor like E3Ad could help to answer.  
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